Phenylethanoid glycosides as a possible COVID-19 protease inhibitor: a virtual screening approach.
J Mol Model
; 27(11): 341, 2021 Nov 03.
Article
in English
| MEDLINE | ID: covidwho-1499466
ABSTRACT
From the beginning of pandemic, more than 240 million people have been infected with a death rate higher than 2%. Indeed, the current exit strategy involving the spreading of vaccines must be combined with progress in effective treatment development. This scenario is sadly supported by the vaccine's immune activation time and the inequalities in the global immunization schedule. Bringing the crises under control means providing the world population with accessible and impactful new therapeutics. We screened a natural product library that contains a unique collection of 2370 natural products into the binding site of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro). According to the docking score and to the interaction at the active site, three phenylethanoid glycosides (forsythiaside A, isoacteoside, and verbascoside) were selected. In order to provide better insight into the atomistic interaction and test the impact of the three selected compounds at the binding site, we resorted to a half microsecond-long molecular dynamics simulation. As a result, we are showing that forsythiaside A is the most stable molecule and it is likely to possess the highest inhibitory effect against SARS-CoV-2 Mpro. Phenylethanoid glycosides also have been reported to have both protease and kinase activity. This kinase inhibitory activity is very beneficial in fighting viruses inside the body as kinases are required for viral entry, metabolism, and/or reproduction. The dual activity (kinase/protease) of phenylethanoid glycosides makes them very promising anit-COVID-19 agents.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Coronavirus Protease Inhibitors
/
Coronavirus 3C Proteases
/
Glycosides
Type of study:
Prognostic study
Topics:
Traditional medicine
/
Vaccines
Language:
English
Journal:
J Mol Model
Journal subject:
Molecular Biology
Year:
2021
Document Type:
Article
Affiliation country:
S00894-021-04963-2
Similar
MEDLINE
...
LILACS
LIS